**Core Concept**
Rosiglitazone is a thiazolidinedione (TZD) that acts as an insulin sensitizer. It enhances insulin's effect on glucose metabolism by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), a transcription factor that regulates gene expression involved in glucose and lipid metabolism.

**Why the Correct Answer is Right**
The activation of PPAR-γ by rosiglitazone increases the expression of genes involved in glucose uptake, such as glucose transporter type 4 (GLUT4). This results in improved insulin sensitivity, allowing glucose to enter cells more effectively. Rosiglitazone also decreases hepatic glucose production and increases fatty acid oxidation, further contributing to its glucose-lowering effects.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is not a known mechanism of action for rosiglitazone. Rosiglitazone does not act as a direct insulin mimetic or a glucagon antagonist.
* **Option B:** This option is incorrect as rosiglitazone does not primarily work by inhibiting pancreatic alpha-cell glucagon secretion. While it may have some effect on glucagon levels, this is not its primary mechanism of action.
* **Option C:** This option is incorrect as rosiglitazone does not work by inhibiting the enzyme aldose reductase. Aldose reductase inhibitors are a different class of drugs used to treat diabetic complications.

**Clinical Pearl / High-Yield Fact**
TZDs like rosiglitazone have been associated with an increased risk of heart failure, particularly in patients with pre-existing cardiovascular disease. Monitor patients for signs and symptoms of heart failure, and use caution when initiating TZDs in high-risk patients.

**Correct Answer: C. Activation of PPAR-γ**